Company & Sponsor Intelligence

Boehringer Ingelheim

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials19

Recruiting0

Completed18

Countries2

Therapeutic footprint

alzheimersdepressionother_neurologyparkinsonsptsdschizophreniastroke

Indexed studies

NCT01097421Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s Disease
parkinsons · COMPLETED

NCT02337907BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.
alzheimers · United StatesPHASE2

NCT00144300Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients
parkinsons · United StatesPHASE4

NCT04860830CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia
schizophrenia · United StatesPHASE3

NCT04846881Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)
schizophrenia · United StatesPHASE3

NCT05103657A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder
ptsd · United StatesPHASE2

NCT01671007GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
stroke · AustriaCOMPLETED

NCT04846868Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)
schizophrenia · United StatesPHASE3

NCT00297778Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms
parkinsons · AustriaPHASE4

NCT04602221A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine
other_neurology · United StatesPHASE1

NCT04937829A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication
depression · United StatesPHASE1

NCT02248220Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease
parkinsons · COMPLETED

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →